Your browser doesn't support javascript.
loading
Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors.
Chen, Rita E; Gorman, Matthew J; Zhu, Daniel Y; Carreño, Juan Manuel; Yuan, Dansu; VanBlargan, Laura A; Burdess, Samantha; Lauffenburger, Douglas A; Kim, Wooseob; Turner, Jackson S; Droit, Lindsay; Handley, Scott A; Chahin, Salim; Deepak, Parakkal; O'Halloran, Jane A; Paley, Michael A; Presti, Rachel M; Wu, Gregory F; Krammer, Florian; Alter, Galit; Ellebedy, Ali H; Kim, Alfred H J; Diamond, Michael S.
Afiliação
  • Chen RE; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Gorman MJ; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
  • Zhu DY; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
  • Carreño JM; Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Yuan D; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • VanBlargan LA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
  • Burdess S; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Lauffenburger DA; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Kim W; Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Turner JS; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
  • Droit L; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
  • Handley SA; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
  • Chahin S; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
  • Deepak P; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
  • O'Halloran JA; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Paley MA; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Presti RM; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Wu GF; Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  • Krammer F; Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, Saint Louis, MO, USA.
  • Alter G; Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, Saint Louis, MO, USA.
  • Ellebedy AH; Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
  • Kim AHJ; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Diamond MS; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Med ; 2(12): 1327-1341.e4, 2021 Dec 10.
Article em En | MEDLINE | ID: mdl-34812429
BACKGROUND: Although vaccines effectively prevent coronavirus disease 2019 (COVID-19) in healthy individuals, they appear to be less immunogenic in individuals with chronic inflammatory disease (CID) or receiving chronic immunosuppression therapy. METHODS: Here we assessed a cohort of 77 individuals with CID treated as monotherapy with chronic immunosuppressive drugs for antibody responses in serum against historical and variant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viruses after immunization with the BNT162b2 mRNA vaccine. FINDINGS: Longitudinal analysis showed the greatest reductions in neutralizing antibodies and Fc effector function capacity in individuals treated with tumor necrosis factor alpha (TNF-α) inhibitors (TNFi), and this pattern appeared to be worse against the B.1.617.2 delta virus. Within 5 months of vaccination, serum neutralizing titers of all TNFi-treated individuals tested fell below the presumed threshold correlate for antibody-mediated protection. However, TNFi-treated individuals receiving a third mRNA vaccine dose boosted their serum neutralizing antibody titers by more than 16-fold. CONCLUSIONS: Vaccine boosting or administration of long-acting prophylaxis (e.g., monoclonal antibodies) will likely be required to prevent SARS-CoV-2 infection in this susceptible population. FUNDING: This study was supported by grants and contracts from the NIH (R01 AI157155, R01AI151178, and HHSN75N93019C00074; NIAID Centers of Excellence for Influenza Research and Response (CEIRR) contracts HHSN272201400008C and 75N93021C00014; and Collaborative Influenza Vaccine Innovation Centers [CIVIC] contract 75N93019C00051).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / Tratamento Farmacológico da COVID-19 Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / Tratamento Farmacológico da COVID-19 Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article